

Date: April 6, 2026

To NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Symbol: AUROPHARMA	To BSE LIMITED Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 001 Scrip Code: 524804
--	--

Re: Information under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

This is to inform you that the Board of Directors of Aurobindo Pharma Limited (“the Company”) at its meeting held today i.e. April 6, 2026 has approved the transfer of the Company’s domestic branded generic pharmaceutical formulations products business on a going concern basis through a Business Transfer Agreement (“BTA”) to Auropharm Limited (previously known as Auro Pharma Limited), a wholly owned subsidiary of the Company. It is in line with the Company’s strategy in further streamlining and accelerating Company’s domestic business for faster growth.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as ‘**Annexure A**’.

We would like to inform you that the said meeting commenced at 7:00 a.m. and concluded at 8:10 a.m .

This is for your information and record.

Thanking you,

Yours faithfully,

For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary

Encl.: As above

(CIN : L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED
www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Annexure A

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1. The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year;	Amount of Turnover contributed: Rs. 1,753.40 Million As a %: 0.55% of consolidated turnover of the listed entity Amount of net worth contributed: Rs. 1,481.40 Million As a %: 0.45% of consolidated net worth of the listed entity
2. Date on which the agreement for sale has been entered into;	The Business Transfer Agreement (“BTA”) is executed on 06 th April, 2026.
3. The expected date of completion of sale/disposal;	The completion of sale is estimated within 90 to 120 days from the date of BTA, subject to satisfactory completion of customary conditions precedent in accordance with the provisions of the BTA. Once completed, the economic benefits of the business shall be transferred to Auropharm Limited from April 1, 2026.
4. Consideration received from such sale/disposal;	Transfer of domestic branded generic pharmaceutical formulations products business will be done for a lumpsum consideration of INR 143.21 Crores (Rs. One Hundred Forty-Three Crores and Twenty-One Lakhs only) subject to such adjustments as provided for in the BTA.
5. Brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof;	Auropharm Limited (previously known as Auro Pharma Limited) is a wholly owned subsidiary of the Company and does not belong to the promoter/ promoter group. Auropharm Limited is engaged, inter alia, in the business of trade of branded generic formulations and pharmaceuticals products in India.
6. Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”;	The buyer, Auropharm Limited, is a wholly owned subsidiary of the Company and the two are related parties as per Regulation 2(zb) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

	<p>The transaction is being undertaken between holding company and its wholly owned subsidiary and accordingly there is no impact on consolidated basis.</p> <p>As per provisions of Section 188 of the Companies Act, 2013 and Regulation 23(5)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, provisions relating to related party transactions are not applicable in respect of transactions between holding company and its wholly owned subsidiary.</p>
<p>7. Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement?</p> <p>If yes, details of the same including compliance with regulation 37A of Listing Regulations;</p>	<p>Yes, the transaction is outside the Scheme of Arrangement.</p> <p>Regulation 37A(1) of SEBI Listing Regulations is not applicable as the transaction is on a slump sale basis and not the sale of whole or substantially the whole of the undertaking of the Company within the meaning of Section 180(1)(a) of the Companies Act, 2013.</p> <p>Further, the accounts of Auropharm Limited will be consolidated with the Company.</p>
<p>Additional disclosures as the transaction is on a slump sale basis</p>	
<p>8. (i) names of entities forming part of the slump sale, details in brief such as, size, turnover etc.;</p>	<p>Aurobindo Pharma Limited (“the Company”) proposes to transfer its domestic branded generic formulations pharmaceuticals products business, on a going concern basis, by the way of slump sale along with all the related assets and liabilities, including but not limited to movable assets, employees, contracts, intellectual property, licenses, permits, consents, approvals, trade receivables, inventory, trade payables to Auropharm Limited.</p> <p>The standalone revenue of Aurobindo Pharma Limited for the year ended March 31, 2025 was Rs. 1,09,333 million and the standalone revenue of domestic branded generic formulations pharmaceuticals products business for the year ended March 31, 2025 was Rs. 1,753.40 million.</p> <p>The turnover of Auropharm Limited for the year ended March 31, 2025 was Nil.</p>
<p>(ii) whether the transaction would fall within related party transactions? If yes, whether the same is done at ‘arm’s length’;</p>	<p>As specified in (6) above.</p>

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

(iii) area of business of the entities;	<p>The Company is engaged in formulating, manufacturing, distribution, marketing and sales of a wide range of pharmaceuticals, APIs and injectables and research and development in several countries with a multi-product portfolio.</p> <p>Auropharm Limited is engaged in the business of trade of branded generic formulations and pharmaceuticals products in India.</p>
(iv) rationale for slump sale;	<p>The slump sale is in line with the Group's objective to consolidate the domestic pharmaceuticals business under the wholly owned subsidiary, which currently operates the non-oncology formulations business acquired from Khandelwal Laboratories Limited.</p> <p>This transaction will assist the Group in expanding their domestic pharmaceuticals business with greater operational efficiency focused approach towards the business.</p>
(v) in case of cash consideration - amount or otherwise share exchange ratio;	As specified in point (4) above.
(vi) brief details of change in shareholding pattern (if any) of listed entity.	There is no change in shareholding pattern of the Company.

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833

Email: info@aurobindo.com Website: www.aurobindo.com